Heparin-Antithrombin Complex (ATH)

The Heparin-Antithrombin complex is a critical anticoagulant mechanism in the body. Antithrombin circulates at high concentration but only becomes capable of efficient thrombin inhibition upon interaction with heparin or related glycosaminoglycans[1]. When heparin binds to antithrombin through a specific pentasaccharide sequence, it causes a conformational change in antithrombin that dramatically enhances its inhibitory activity against thrombin and factor Xa[3][6]. For thrombin inhibition, both antithrombin and thrombin must bind to the same heparin chain, requiring a minimum heparin length of 18 saccharide units[6][8]. In contrast, factor Xa inhibition only requires the pentasaccharide binding site. The complex exhibits different activities against free versus bound thrombin. While it effectively inhibits free thrombin in the liquid phase, the AT-heparin complex has limited activity against thrombin bound to fibrin because heparin also binds to both fibrin and thrombin, facilitating accumulation of thrombin in a "protected" active state[4]. The anticoagulant properties of therapeutic heparin are mediated by its interaction with antithrombin, making this complex a crucial target for anticoagulant therapies[1]. Covalent antithrombin-heparin complexes have been developed that demonstrate potent anticoagulant activity with potentially improved efficacy and safety profiles compared to standard heparin[4].

Other names

Antithrombin-Heparin Covalent ComplexAntithrombin-thrombin-heparin ternary complexAT-heparin complex

Conformational activation of antithrombin Template-based inhibition of coagulation factors Ternary complex formation Allosteric enhancement of inhibitory activity